- Home
- CRVS vs GMGI Comparison
CRVS vs GMGI Comparison
Compare CRVS & GMGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- GMGI
- Stock Information
- Founded
- CRVS 2014
- GMGI 2008
- Country
- CRVS United States
- GMGI United States
- Employees
- CRVS N/A
- GMGI N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- GMGI Computer Software: Prepackaged Software
- Sector
- CRVS Health Care
- GMGI Technology
- Exchange
- CRVS Nasdaq
- GMGI Nasdaq
- Market Cap
- CRVS 257.0M
- GMGI 255.9M
- IPO Year
- CRVS 2016
- GMGI N/A
- Fundamental
- Price
- CRVS $2.82
- GMGI $1.92
- Analyst Decision
- CRVS Strong Buy
- GMGI Strong Buy
- Analyst Count
- CRVS 5
- GMGI 1
- Target Price
- CRVS $12.63
- GMGI $4.00
- AVG Volume (30 Days)
- CRVS 724.1K
- GMGI 115.0K
- Earning Date
- CRVS 05-05-2025
- GMGI 05-12-2025
- Dividend Yield
- CRVS N/A
- GMGI N/A
- EPS Growth
- CRVS N/A
- GMGI N/A
- EPS
- CRVS N/A
- GMGI N/A
- Revenue
- CRVS N/A
- GMGI $151,115,532.00
- Revenue This Year
- CRVS N/A
- GMGI $36.68
- Revenue Next Year
- CRVS N/A
- GMGI N/A
- P/E Ratio
- CRVS N/A
- GMGI N/A
- Revenue Growth
- CRVS N/A
- GMGI 62.50
- 52 Week Low
- CRVS $1.30
- GMGI $1.70
- 52 Week High
- CRVS $10.00
- GMGI $6.27
- Technical
- Relative Strength Index (RSI)
- CRVS 25.66
- GMGI 49.97
- Support Level
- CRVS $2.56
- GMGI $1.85
- Resistance Level
- CRVS $3.31
- GMGI $2.05
- Average True Range (ATR)
- CRVS 0.37
- GMGI 0.11
- MACD
- CRVS -0.08
- GMGI -0.01
- Stochastic Oscillator
- CRVS 12.75
- GMGI 53.99
Stock Price Comparison Chart: CRVS vs GMGI
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About GMGI Golden Matrix Group Inc.
Golden Matrix Group Inc is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers, located in the Asia Pacific region. The company operates in two reportable segments; B2B and B2C. The B2C segment earns majority revenue. The company operates in UK, Asia Pacific and Latin America. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, R Kings Competitions and GM-AG.